Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Trial to Evaluate the EBA, Safety and Tolerability of Ethionamide Alone and in Combination With BVL-GSK098 Administered Orally to Adults With Newly Diagnosed, Rifampicin- and Isoniazid-Susceptible Pulmonary Tuberculosis

Next Previous
Search
Trial Profile

A Phase 2 Trial to Evaluate the EBA, Safety and Tolerability of Ethionamide Alone and in Combination With BVL-GSK098 Administered Orally to Adults With Newly Diagnosed, Rifampicin- and Isoniazid-Susceptible Pulmonary Tuberculosis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 25 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alpibectir (Primary) ; Ethionamide (Primary) ; Isoniazid
  • Indications Pulmonary tuberculosis
  • Focus Proof of concept; Therapeutic Use
  • Acronyms BETO

    • Most Recent Events

    • 16 Oct 2024 Status changed from recruiting to completed as per a BioVersys media release.
    • 12 Dec 2023 According to a BioVersys AG media release, the TRIC-TB Project continues to receive funding from the EU IMI-JU2 programme under the AMR Accelerator umbrella and from the European & Developing Countries Clinical Trials Partnership (EDCTP2 programme) for the bEto-TB Project (Phase 2a).
    • 30 Jan 2023 According to a BioVersys media release, first patient has been dosed in this study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top